CTIS2023-505211-21-00进行中（未招募）1 期
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BO44178
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, Histologically or cytologically documented locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative surgery and/or definitive chemoradiotherapy, No prior systemic treatment for metastatic NSCLC, Known tumor PD-L1 status, Confirmed availability of representative tumor specimens, Adequate hematologic and end-organ function
排除标准
- •NSCLC known to have a mutation in the EGFR gene or an ALK fusion oncogene. Known targetable c-ROS oncogene 1 (ROS1), BRAFV600E or rearranged during transfection (RET) proto-oncogene genomic aberrations, Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases. Untreated or clinically unstable spinal cord compression, History of leptomeningeal disease, Uncontrolled tumor-related pain. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently), Active or history of autoimmune disease or immune deficiency
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ARTHIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 x 10^6/L and who meet the other inclusion and exclusion criteria of the protocolMedDRA version: 12.0Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-006302-13-DEBionor Immuno AS120
进行中（未招募）
1 期
Study to compare oral Nafithromycin with Oral Moxifloxacin in the treatment of Pneumonia in Adults.EUCTR2016-001246-26-BGWockhardt Bio AG225
进行中（未招募）
1 期
Study to compare oral Nafithromycin with Oral Moxifloxacin in the treatment of Pneumonia in Adults.Community-Acquired Bacterial PneumoniaMedDRA version: 19.0Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862EUCTR2016-001246-26-LVWockhardt Bio AG225
进行中（未招募）
不适用
A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ARTHIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 x 10^6/L and who meet the other inclusion and exclusion criteria of the protocolMedDRA version: 12.0Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-006302-13-GBBionor Immuno AS120
进行中（未招募）
1 期
A Clinical Study to Evaluate the Safety and Efficacy of Injections of Cells from another person for the Treatment of Subjects with Intermittent Claudication (IC).EUCTR2011-004091-12-DEPluristem Ltd.150